<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Sun Pharma</title>
	<atom:link href="http://www.tapanray.in/tag/sun-pharma/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Unleashing Pharma’s New Potential In Changing Market Dynamics</title>
		<link>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unleashing-pharmas-new-potential-in-changing-market-dynamics</link>
		<comments>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/#comments</comments>
		<pubDate>Mon, 07 Jun 2021 00:00:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[changing]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[dynamics]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[plan]]></category>
		<category><![CDATA[potential]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remote working]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TCS]]></category>
		<category><![CDATA[unleashing]]></category>
		<category><![CDATA[WFH]]></category>
		<category><![CDATA[work from home]]></category>
		<category><![CDATA[workplace]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10525</guid>
		<description><![CDATA[Several pharma majors have started pondering in this space. This is evident from several recent developments, both in India, and also in other places of the world. One such articulation can be heard from the very top of the domestic &#8230; <a href="http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unleashing-pharmas-new-potential-in-changing-market-dynamics/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does India Produce ‘World Class’ Medicines, For All?</title>
		<link>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-india-produce-world-class-medicines-for-all</link>
		<comments>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/#comments</comments>
		<pubDate>Mon, 12 Oct 2015 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA['import bans']]></category>
		<category><![CDATA['pharmacy of the world']]></category>
		<category><![CDATA[anti-epileptic]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Biosciences]]></category>
		<category><![CDATA[class]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Elepsia XR]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[export]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[GVK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[NBER]]></category>
		<category><![CDATA[numero uno]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[quality. cGMP]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[SPARC]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7160</guid>
		<description><![CDATA[India has already achieved a staggering number In terms of quantity or volume of generic medicines that it produces not just for India, but for many developed, developing and poorer countries, across the world. For this reason, India is popularly &#8230; <a href="http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-india-produce-world-class-medicines-for-all/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drug Price Control in India: A Fresh Advocacy With Blunt Edges</title>
		<link>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges</link>
		<comments>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/#comments</comments>
		<pubDate>Mon, 07 Sep 2015 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2011]]></category>
		<category><![CDATA[2013]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[blunt]]></category>
		<category><![CDATA[campaign]]></category>
		<category><![CDATA[capita]]></category>
		<category><![CDATA[cheapest]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[cutting]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[edges]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[income]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Para 19]]></category>
		<category><![CDATA[parity]]></category>
		<category><![CDATA[per]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pharmasofttech]]></category>
		<category><![CDATA[power]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[purchasing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Subburaj]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Yeh dil maange more]]></category>
		<category><![CDATA[“Assessing the Impact of Price Control Measures on Access to Medicines in India”]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7017</guid>
		<description><![CDATA[It is no-brainer that the advocacy initiatives to influence the new Government doing away with the ‘Drug Price Control’ in India has re-started by flooring the gas pedal. A fresh invigorating effort, apparently a pretty expensive one, has been initiated &#8230; <a href="http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drug-price-control-in-india-a-fresh-advocacy-with-blunt-edges/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“Make in India” Image of Pharma Needs An Early Makeover</title>
		<link>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=make-in-india-image-of-pharma-needs-an-early-makeover</link>
		<comments>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/#comments</comments>
		<pubDate>Mon, 20 Apr 2015 00:00:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AIOCD]]></category>
		<category><![CDATA[AllianceBoots]]></category>
		<category><![CDATA[Amerisource –Bergen]]></category>
		<category><![CDATA[AWACS]]></category>
		<category><![CDATA[Cardinal Health]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[Celesio]]></category>
		<category><![CDATA[CVS Caremark]]></category>
		<category><![CDATA[Data Integrity.]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[GMP]]></category>
		<category><![CDATA[image]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ipca]]></category>
		<category><![CDATA[Make in India]]></category>
		<category><![CDATA[makeover]]></category>
		<category><![CDATA[McKesson]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Ministry of Commerce]]></category>
		<category><![CDATA[Modi]]></category>
		<category><![CDATA[pharma export]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacy distributors]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Stefano Pessina]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Walgreen]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6549</guid>
		<description><![CDATA[“It is never too late to be what you might have been” - George Elliot The chronicle of events since the last couple of years or so, related to ‘Make in India’ image of the local drug industry, have been instrumental &#8230; <a href="http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/make-in-india-image-of-pharma-needs-an-early-makeover/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Drug Pricing Freedom Benefit Patients in A Free-Market Economy?</title>
		<link>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy</link>
		<comments>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/#comments</comments>
		<pubDate>Mon, 13 Oct 2014 00:00:40 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[(NCPA)]]></category>
		<category><![CDATA[Committee on Oversight and Government Reform]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Cummings]]></category>
		<category><![CDATA[DPCO]]></category>
		<category><![CDATA[Dr. Reddy’s Laboratories]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[free-market]]></category>
		<category><![CDATA[freedom]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Myth]]></category>
		<category><![CDATA[National Community Pharmacists Association]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Senator Bernard Sanders]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[update]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[Zydus Cadila]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6094</guid>
		<description><![CDATA[A 2010 USFDA update titled ‘Generic Competition and Drug Prices’ highlighted that generic competition is intimately associated with lower drug prices, and the entry of the second generic competitor is associated with the largest price reduction. The agency found that &#8230; <a href="http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-drug-pricing-freedom-benefit-patients-in-a-free-market-economy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Horizon: Cloud, Rainbow And Smear</title>
		<link>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-horizon-cloud-rainbow-and-smear</link>
		<comments>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/#comments</comments>
		<pubDate>Mon, 09 Dec 2013 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[10]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[Biocon]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cloudy]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[expiry]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[monster]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[rainbow]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[sky]]></category>
		<category><![CDATA[Sun Pharma]]></category>
		<category><![CDATA[taint]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[top]]></category>
		<category><![CDATA[total]]></category>
		<category><![CDATA[Trastuzumab]]></category>
		<category><![CDATA[UKMHRA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[VUCA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=4400</guid>
		<description><![CDATA[Some recent papers contemplated that the patent cliff for blockbuster drugs has already reached the zenith and early signs of recovery should be visible from 2013 onwards. However, from analysis of the currently available data, contrary to the above belief, I reckon, the downtrend &#8230; <a href="http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-horizon-cloud-rainbow-and-smear/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
